Taysha Gene Therapies, Inc. (TSHA)
NASDAQ: TSHA · IEX Real-Time Price · USD
2.140
-0.120 (-5.31%)
At close: Jul 19, 2024, 4:00 PM
2.150
+0.010 (0.47%)
Pre-market: Jul 22, 2024, 7:34 AM EDT
Taysha Gene Therapies Revenue
Taysha Gene Therapies had revenue of $14.16M in the twelve months ending March 31, 2024, with 96.39% growth year-over-year. Revenue in the quarter ending March 31, 2024 was $3.41M. In the year 2023, Taysha Gene Therapies had annual revenue of $15.45M with 517.55% growth.
Revenue (ttm)
$14.16M
Revenue Growth
+96.39%
P/S Ratio
30.44
Revenue / Employee
$272,231
Employees
52
Market Cap
430.95M USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 15.45M | 12.95M | 517.55% |
Dec 31, 2022 | 2.50M | - | - |
Dec 31, 2021 | 0 | - | - |
Dec 31, 2020 | 0 | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionTSHA News
- 17 days ago - Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 25 days ago - Taysha Gene Therapies Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants - GlobeNewsWire
- 26 days ago - Worthington Enterprises Posts Downbeat Results, Joins Taysha Gene Therapies, General Mills And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session - Benzinga
- 26 days ago - Taysha Gene Therapies Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants - GlobeNewsWire
- 4 weeks ago - What's Going On With Taysha Gene Therapies Stock Tuesday? - Benzinga
- 4 weeks ago - Taysha Gene Therapies Announces Positive Clinical Data Across Adult and Pediatric Patients from Low Dose Cohort in Ongoing REVEAL Phase 1/2 Trials Evaluating TSHA-102 in Rett Syndrome - GlobeNewsWire
- 5 weeks ago - Taysha Gene Therapies to Present Clinical Data from Both REVEAL Phase 1/2 Trials During Company-Hosted Webcast and at 2024 IRSF Rett Syndrome Scientific Meeting - GlobeNewsWire
- 2 months ago - Taysha Gene Therapies Reports First Quarter 2024 Financial Results and Provides Corporate Update - GlobeNewsWire